Home
This site is intended for healthcare professionals

Advancing Pompe Care - Detecting Change in Adults with LOPD: Module 2 Detecting Subclinical Progression

Share

Description

This activity is supported by an independent educational grant from Amicus.

Join Barbara Burton, MD, Emeritus Professor, Northwestern University in exploring how no single measure can capture the full clinical picture in Pompe disease. This module examines how complementary assessments across motor, respiratory, structural, biochemical, and patient-reported domains can be combined to identify progression, understand discordant findings, and support a more complete assessment of disease status.

Session highlights

  • Monitor across complementary domains using functional, respiratory, imaging, biochemical, and patient-reported measures.
  • Recognize respiratory decline early by incorporating upright and supine respiratory measures and assessing for nocturnal hypoventilation.
  • Use patient-reported outcomes alongside clinical measures to capture fatigue, activity limitations, and changes that may not be apparent during clinic testing.
  • Interpret discordance carefully by confirming changes, considering alternative explanations, and looking for convergence across domains before drawing conclusions.

This is Module Two of Three, find Modules One and Three here.

Who Should Participate

This program is designed for healthcare practitioners treating adults with Late-Onset Pompe Disease (LOPD), including:

  • Primary Care Leads: Including neuromuscular specialists, neurologists, and metabolic disease specialists involved in direct monitoring, ongoing treatment, and disease management.
  • Multidisciplinary Team Members: Including pulmonologists/respiratory physicians, geneticists, genetic counselors, rehabilitation specialists, advanced practice providers (NPs/PAs), and neuromuscular nurses involved in comprehensive LOPD care.

Prefer to read? See our Key Clinical Summary Here.

Faculty

Barbara Burton, MD, Emeritus Professor, Northwestern University

Barbara K. Burton, MD, is a medical geneticist and faculty member at Northwestern University Feinberg School of Medicine. Triple-board-certified in pediatrics, clinical genetics, and clinical biochemical genetics. Dr. Burton’s clinical practice and research focus on the diagnosis, management, and treatment of inherited metabolic disorders and rare genetic conditions. She possesses specialized expertise in disorders identified through newborn screening—such as phenylketonuria (PKU)—as well as lysosomal storage disorders, and actively serves as an investigator in clinical trials evaluating novel therapies for rare diseases.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Prof. Em. Barbara Burton has the following relevant financial relationships: BioMarin: Speaker, consultant; Chiesi: Speaker; Denali: Speaker, consultant; JCR Pharma: Consultant; Moderna: Consultant.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 26th 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting October 13th 2026, and will expire on October 26th 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

By the end of this program HCP's should be better able to:

  1. Recognise patterns of suboptimal clinical response in adults with LOPD through analysis of longitudinal motor, respiratory, and functional data to distinguish true disease stability from progressive decline. • Correlate changes in six-minute walk distance, timed function tests, and patient-reported fatigue with early loss of functional reserve despite apparent stability. • Identify respiratory deterioration using trends in upright and supine spirometry, nocturnal symptoms, or non-invasive ventilation requirements. • Differentiate treatment-related plateaus from natural disease progression by integrating baseline severity, duration of therapy, and trajectory of change. • Trigger timely reassessment and rigorous clinical documentation of management strategies when objective or subjective indicators suggest loss of therapeutic benefit.

  2. Integrate multimodal monitoring data, including imaging, respiratory metrics, laboratory indicators, and patient-reported outcomes, to identify clinically meaningful disease progression. • Interpret quantitative imaging findings, respiratory metrics, laboratory indicators, and patient-reported outcomes as complementary measures of disease activity. • Integrate positional spirometry (e.g., upright and supine forced vital capacity) and inspiratory/expiratory pressure testing to identify early diaphragmatic weakness masked by standard upright assessments. • Recognise discordance between functional tests and structural or biochemical markers that may signal subclinical progression. • Use longitudinal data to determine when observed changes warrant closer surveillance, supportive intervention, or modification of management plans.

  3. Develop individualised, patient-centred management plans that address evolving disease burden, treatment goals, and functional outcomes across the adult LOPD continuum. • Appraise the mechanisms of action, clinical trial data, and safety profiles of existing and next-generation enzyme replacement therapies to identify appropriate candidates for treatment optimisation. • Evaluate disease stage, progression patterns, and comorbidities when considering adjustments to therapy or supportive care. • Balance anticipated benefits, treatment burden, and patient priorities when selecting among available management options. • Incorporate multidisciplinary input from neuromuscular, respiratory, and rehabilitation teams to optimise long-term outcomes. • Facilitate shared decision-making discussions that clarify expectations, define meaningful clinical goals, and document response over time.

Similar communities

View all

Similar events and on demand videos